SCM
CSTL icon

Stonepine Capital Management’s Castle Biosciences CSTL Stock Holding History

Stonepine Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-91,978
Closed -$1.26M – 24
2023
Q2 		$1.26M Sell
91,978
-200,888
-69% -$4.07M 0.46% 20
2023
Q1 		$6.65M Buy
292,866
+114,626
+64% +$2.8M 2.23% 11
2022
Q4 		$4.2M Buy
+178,240
New +$4.13M 1.77% 12
2022
Q3 		– Sell
-295,372
Closed -$6.48M – 22
2022
Q2 		$6.48M Buy
+295,372
New +$6.86M 3.02% 15

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stonepine Capital Management's CSTL Position: Q3 2023 in Review

Stonepine Capital Management sold out of Castle Biosciences (CSTL) in Q3 2023, closing a stake of 91,978 shares — an estimated $1.26M sold.

Stonepine Capital Management first reported a position in CSTL in Q2 2022 and held it in 4 quarters. The position peaked at $6.65M in Q1 2023. 135 funds tracked by Wall St. Rank hold CSTL as of Q3 2023.

  • Stonepine Capital Management reported no remaining Castle Biosciences position as of Q3 2023 after selling out during the quarter.
  • Stonepine Capital Management sold 91,978 Castle Biosciences shares in Q3 2023, an estimated $1.26M.
  • Stonepine Capital Management first reported a position in Castle Biosciences in Q2 2022 and held it in 4 quarters.
  • Stonepine Capital Management's Castle Biosciences position peaked at $6.65M in Q1 2023.
  • 135 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2023.

Based on Stonepine Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.